Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: A qualitative and quantitative assessment

The Lancet Infectious Diseases

Volumn 13, Issue 5, 2013, Pages 416-425

  Vogel, Ulrich ^a   Taha, Muhamed Kheir ^b   Vazquez, Julio A ^c   Findlow, Jamie ^d   Claus, Heike ^a   Stefanelli, Paola ^e   Caugant, Dominique A ^f   Kriz, Paula ^g   Abad, Raquel ^c   Bambini, Stefania ^h   Carannante, Anna ^e   Deghmane, Ala Eddine ^b   Fazio, Cecilia ^e   Frosch, Matthias ^a   Frosi, Giacomo ^h   Gilchrist, Stefanie ^d   Giuliani, Marzia M ^h   Hong, Eva ^b   Ledroit, Morgan ^b   Lovaglio, Pietro G ^j   Lucidarme, Jay ^d   Musilek, Martin ^g   Muzzi, Alessandro ^h   Oksnes, Jan ^f   Rigat, Fabio ^h   Orlandi, Luca ^h   Stella, Maria ^h   Thompson, Danielle ^d   Pizza, Mariagrazia ^h   Rappuoli, Rino ^h   Serruto, Davide ^h   Comanducci, Maurizio ^h   Boccadifuoco, Giuseppe ^h   Donnelly, John J ⁱ   Medini, Duccio ^h   Borrow, Ray ^d   more..

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b INSTITUT PASTEUR   (France)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^f NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^g NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^h NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

ⁱ Novartis Vaccines and Diagnostic   (United States)

^j UNIVERSITY OF MILANO BICOCCA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE;

ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CZECH REPUBLIC; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPE; FRANCE; GERMANY; ITALY; MULTILOCUS SEQUENCE TYPING; NEISSERIA MENINGITIDIS; NONHUMAN; NORWAY; PRIORITY JOURNAL; SPAIN;

ADHESINS, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL TYPING TECHNIQUES; DNA, BACTERIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EUROPE; GENES, BACTERIAL; GENOTYPE; GEOGRAPHY; HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; MULTILOCUS SEQUENCE TYPING; NEISSERIA MENINGITIDIS, SEROGROUP B; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS;

EID: 84876725387     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70006-9     Document Type: Article

References (28)

1. Tan LK, Carlone GM, Borrow R Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010, 362:1511-1520.
2. Sadarangani M, Pollard AJ Serogroup B meningococcal vaccines-an unfinished story. Lancet Infect Dis 2010, 10:112-124.
3. Livorsi DJ, Stenehjem E, Stephens DS Virulence factors of gram-negative bacteria in sepsis with a focus on Neisseria meningitidis. Contrib Microbiol 2011, 17:31-47.
4. Feil EJ, Holmes EC, Bessen DE, et al. Recombination within natural populations of pathogenic bacteria: short-term empirical estimates and long-term phylogenetic consequences. Proc Natl Acad Sci USA 2001, 98:182-187.
5. Borrow R, Miller E Surrogates of protection. Handbook of meningococcal disease 2006, 323-351. Wiley-Blackwell, Oxford. M. Frosch, M. Maiden (Eds.).
6. Donnelly J, Medini D, Boccadifuoco G, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 2010, 107:19490-19495.
7. Ruijne N, Lea RA, O'Hallahan J, Oster P, Martin D Understanding the immune responses to the meningococcal strain-specific vaccine MeNZB measured in studies of infants. Clin Vaccine Immunol 2006, 13:797-801.
8. Annual epidemiological report on communicable diseases in Europe 2010 2010, 139-142. European Centre for Disease Prevention and Control, ECDC, Stockholm.
9. Invasive Neisseria meningitidis in Europe 2006 2006, EU-IBIS Network, Health Protection Agency, London.
10. Lucidarme J, Comanducci M, Findlow J, et al. Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin Vaccine Immunol 2010, 17:919-929.
11. Bambini S, Muzzi A, Olcen P, Rappuoli R, Pizza M, Comanducci M Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 2009, 27:2794-2803.
12. Plikaytis B, Stella M, Boccadifuoco G, et al. Inter-laboratory standardization of the sandwich ELISA designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clin Vaccine Immunol 2012, 19:1609-1617.
13. Comanducci M, Bambini S, Caugant DA, et al. NadA diversity and carriage in Neisseria meningitidis. Infect Immun 2004, 72:4217-4223.
14. Lucidarme J, Tan L, Exley RM, Findlow J, Borrow R, Tang CM Characterisation of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen, factor H binding protein. Clin Vaccine Immunol 2011, 18:1002-1014.
15. Weynants VE, Feron CM, Goraj KK, et al. Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis. Infect Immun 2007, 75:5434-5442.
16. Brunelli B, Del Tordello E, Palumbo E, et al. Influence of sequence variability on bactericidal activity sera induced by factor H binding protein variant 1.1. Vaccine 2011, 29:1072-1081.
17. Tappero JW, Lagos R, Ballesteros AM, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999, 281:1520-1527.
18. Lucidarme J, Comanducci M, Findlow J, et al. Characterisation of fHbp, nhba (gna2132), nadA, porA, sequence type (ST) and the genomic presence of IS1301 in group B meningococcal ST269 clonal complex case isolates from England and Wales. J Clin Microbiol 2009, 47:3577-3585.
19. Metruccio MM, Pigozzi E, Roncarati D, et al. A novel phase variation mechanism in the meningococcus driven by a ligand-responsive repressor and differential spacing of distal promoter elements. PLoS Pathog 2009, 5:e1000710.
20. Fagnocchi L, Pigozzi E, Scarlato V, Delany I In the NadR regulon, adhesins and diverse meningococcal functions are regulated in response to signals in human saliva. J Bacteriol 2012, 194:460-474.
21. Fagnocchi L, Biolchi A, Ferlicca F, et al. Transcriptional regulation of the nadA gene in Neisseria meningitidis impacts on the prediction of coverage of the 4CMenB vaccine. Infect Immun 2013, 81:560-569.
22. Litt DJ, Savino S, Beddek A, et al. Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease. J Infect Dis 2004, 190:1488-1497.
23. Brehony C, Jolley KA, Maiden MC Multilocus sequence typing for global surveillance of meningococcal disease. FEMS Microbiol Rev 2007, 31:15-26.
24. Pajon R, Fergus AM, Koeberling O, Caugant DA, Granoff DM Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development. PloS Negl Trop Dis 2011, 5:e1302.
25. Bai X, Findlow J, Borrow R Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther 2011, 11:969-985.
26. Santolaya ME, O'Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012, 379:617-624.
27. Gossger N, Snape MD, Yu LM, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012, 307:573-582.
28. Snape MD, Medini D, Halperin SA, DeTora L, Drori J, Moxon ER The challenge of post-implementation surveillance for novel meningococcal vaccines. Vaccine 2012, 30(suppl 2):B67-B72.